The AI GI & Liver Research Intelligence agent — gut & liver, bench to real-world.
A scientific research agent (not a chatbot, not a diagnostic tool) that discovers, connects, analyses, challenges and synthesises gastroenterology & hepatology knowledge from authorized literature, databases, datasets and enterprise tools — to help you understand what is known, what is unknown, what may be true, what has failed and what to test next.
Twelve deeply-connected knowledge domains spanning the research lifecycle.
IBD (Crohn's, UC), MASLD/MASH & cirrhosis, viral & autoimmune hepatitis, IBS, GERD, celiac, pancreatitis and GI/hepatobiliary malignancies.
Intestinal epithelium & barrier function, hepatocyte & stellate-cell biology, bile-acid & lipid metabolism, gut–liver & gut–brain axes, mucosal immunity and fibrogenesis.
Gut microbial ecology, dysbiosis, metabolites (SCFAs, bile acids), host–microbe signalling and microbiome-based therapeutics — connected microbe → metabolite → host → phenotype.
Genomics (GWAS, PNPLA3/TM6SF2), single-cell & spatial gut/liver atlases, metagenomics, proteomics and metabolomics — connected across scales.
Human-genetic, functional and multi-omics evidence for GI & liver targets — with tractability, tissue exposure, safety and prior failures clearly separated.
Small molecules, biologics (anti-TNF, IL-23, integrins), FXR/THR-β agonists, RNA therapeutics and live-biotherapeutics — across the discovery-to-development cascade.
Fecal calprotectin, FibroScan/ELF, liver-fat imaging (MRI-PDFF), histology and endotype signatures replacing biopsy — with validation and clinical-utility context.
Design, population, endpoints (endoscopic/histologic remission, MASH resolution, fibrosis stage), comparators, results and adverse events — surfacing failed hypotheses (a hard MASH history) and design opportunities.
Endoscopic & imaging assessment, adherence, real-world effectiveness and safety signals — distinguishing a signal from confirmed causality.
Disease-activity & progression modelling, survival analysis, microbiome statistics, causal inference and multi-omics integration on authorized GI/liver datasets.
Reasons across Disease ↔ Gene ↔ Cell ↔ Microbe ↔ Metabolite ↔ Pathway ↔ Biomarker ↔ Target ↔ Drug ↔ Trial ↔ Outcome, with every claim traceable to primary sources.
Finds conflicting findings, non-responder mechanisms, missing non-invasive biomarkers and poorly-validated targets — then frames testable hypotheses and experiments.
Surface novel, testable research directions and drug-repurposing leads across the whole ecosystem — not a single paper.
Integrate literature, omics, trials and real-world data into one traceable evidence graph so hidden connections become visible.
A built-in scientific critic tests for confounding, batch effects, power, publication bias, replication and prior failures.
Research questions, proposals, protocols, SAPs, reviews and manuscript scaffolds — never fabricating data, patients, stats or citations.
Statements are tagged so you always know their standing — and confidence is stated, never inflated. Citations, DOIs, PMIDs, dataset and trial IDs are drawn from primary sources; if a source can't be verified it says so. Gastroenterology & Hepatology Genius is a research-intelligence system, not a substitute for a physician — it does not diagnose or treat individuals.
We use cookies to run Anxya Health and improve your experience. Choose how we may use them. Read our Cookie Policy, Privacy Policy and Terms.